Aprinoia Therapeutics (Aprinoia Therapeutics) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Aprinoia Therapeutics's net issuance of preferred for the six months ended in Jun. 2023 was $0.00 Mil. The number is 0, which means that Aprinoia Therapeutics has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Aprinoia Therapeutics's net issuance of preferred for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.

Aprinoia Therapeutics Net Issuance of Preferred Stock Historical Data

The historical data trend for Aprinoia Therapeutics's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Net Issuance of Preferred Stock Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Net Issuance of Preferred Stock

31.00

8.96

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Net Issuance of Preferred Stock	-	8.96	-	-

Aprinoia Therapeutics Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

Aprinoia Therapeutics Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines